The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EP-100 + paclitaxel to overcome taxane resistance in patients with recurrent LHRH-receptor expressing ovarian cancer.
 
Alpa Manchandia Nick
No Relationships to Disclose
 
Renata Urban
Research Funding - Vermillion (Inst)
 
Mary E Gordinier
No Relationships to Disclose
 
Carola Leuschner
Employment - Esperance Pharmaceuticals
Stock and Other Ownership Interests - Esperance Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Esperance Pharmaceuticals
 
Thomas Rado
Consulting or Advisory Role - Celgene
 
Linda M. Bavisotto
Consulting or Advisory Role - Cantex Pharmaceuticals; Esperance Pharmaceuticals; Oncothyreon; ResearchPoint Global; Resolve Therapeutics; TD2; Tekmira
Research Funding - Cantex Pharmaceuticals; Esperance Pharmaceuticals; Oncothyreon; ResearchPoint Global; Resolve Therapeutics; TD2; Tekmira
 
John Whisnant
Consulting or Advisory Role - Esperance Pharmaceuticals
Research Funding - Esperance Pharmaceuticals
 
Robert L. Coleman
Honoraria - NCCN
Consulting or Advisory Role - Clovis Oncology; Esperance Pharmaceuticals; Genentech/Roche
Research Funding - Amgen; Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Esperance Pharmaceuticals; Johnson & Johnson; Merrimack; OncoMed
Travel, Accommodations, Expenses - Amgen; Array BioPharma; AstraZeneca/MedImmune; Gradalis; Merck; Merrimack; Millennium